Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common diabetes drug boost brain power in schizophrenia?

NCT ID NCT05838573

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tested whether metformin, a drug used for diabetes, can improve cognitive problems in people with schizophrenia. 120 participants took either metformin or a placebo for 24 weeks. Researchers measured changes in thinking skills and brain scans to see if metformin helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, this could point toward a new way to help with thinking and memory problems in people with schizophrenia.
What could go wrong
This is a completed phase 3 trial, but results are not yet reported. Metformin is generally safe, but it may not improve cognition, and the effect may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

120 people

The number who actually took part.

Started

May 2023

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female aged 18 to 50 years, who meet the Diagnostic and Statistical Manual (DSM-5) diagnostic criteria for schizophrenia. 2. Duration of illness less than 15 years with current symptoms in a stable condition. 3. Participants must be receiving stable treatment with standard-of-care medications, with a maximum allowance of two antipsychotic medications. If additional anticholinergic agents are required for the management of extrapyramidal symptoms, they should be prescribed at low dosages. 4. Have great compliance with medication and follow-up. 5. Meet one of the diagnostic criteria for metabolic syndrome: 1)abdominal obesity (i.e. central obesity): waist circumference for male≥90 cm, for female ≥85 cm; 2)fasting blood glucose ≥110 mg/dl (6.1 mmol/l) and/or plasma glucose ≥140 mg/dl (7.8 mmol/l) after glucose load; 3)at fasting state, triglyceride ≥1.7 mmol/l; 4)at fasting state, HDL-C \<1.04 mmol/L. 6. Signed the study consent for participation. Exclusion Criteria: 1. Having a history of substance dependence or abuse or whose symptoms are caused by other diagnosable mental disorders. 2. Having a history of traumatic brain injury, seizures or other known neurological or organic diseases of the central nervous system. 3. Taking antidepressants, stimulants, mood stabilizers or accepts electricity shock treatment. 4. Having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be managed in an inpatient setting. 5. Taking dementia related drugs, minocycline, and other drugs that could affect cognitive function. 6. The routine blood tests showing significant abnormal renal, liver function or other somatic disease. 7. Pregnant or lactating women. For schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mental Health Institute of Second Xiangya Hospital,CSU

    Changsha, Hunan, 410011, China

  • Shandong Mental Health Center

    Jinan, Shandong, 250014, China

  • The Second People's Hospital of Dali Bai Autonomous Prefecture

    Dali, Yunnan, 671014, China

  • The Third Peoples's Hospital of Jiangyin

    Jiangyin, Jiangsu, 214400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.